Liquidia Corporation logo
Liquidia Corporation LQDA
$ 27.64 2.32%
report update icon

Quarterly report 2026-Q2
added 08-12-2026

Liquidia Corporation Financial Statements 2025-2011 | LQDA

Annual Financial Statements Liquidia Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

2.95 B 2.7 B 957 M 440 M 242 M 103 M 105 M 98.9 M - - - - - - -

Shares

86.1 M 78.7 M 65 M 61 M 49.7 M 37.8 M 18.5 M 7.16 M - - - - - - -

Historical Prices

34.2 34.2 14.7 7.22 4.87 2.95 4.28 21.7 - - - - - - -

Net Income

-68.9 M -130 M -78.5 M -41 M -34.6 M -59.8 -47.6 M -53.1 M -29.2 M -15.9 M - - - - -

Revenue

158 M 14 M 17.5 M 15.9 M 12.9 M 0.74 8.07 M 2.71 M 7.26 M 13.2 M - - - - -

Cost of Revenue

- 5.88 M 2.89 M 2.86 M 3.02 M 238 K - - - - - - - - -

Gross Profit

- - - - - 0.502 7.26 M 2.59 M 6.94 M 12.3 M - - - - -

Operating Income

-51.4 M -121 M -73.4 M -38.8 M -33.8 M -59.1 M -46.8 M - - - - - - - -

Interest Expense

- - 6.27 M 2.34 M 762 K 858 K 1.37 M - - - - - - - -

EBITDA

-49.8 M -119 M -71.2 M -35.1 M -28.2 M 3.07 K -44.3 M -33.3 M -27.1 M -15.2 M - - - - -

Operating Expenses

- - - - - 59.6 54.1 M 37.5 M 35 M 28.2 M - - - - -

General and Administrative Expenses

157 M 81.6 M 44.7 M 32.4 M 23.1 M 27.4 M 13.6 M 8.75 M 10.2 M 4.84 M - - - - -

All numbers in USD currency

Quarterly Income Statement Liquidia Corporation

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

85.6 M 88 M - 86.3 M 85.6 M 85.2 M 84.7 M 78.3 M 76.4 M 75.4 M 68.6 M 64.9 M 64.8 M 64.7 M 64.5 M 64.5 M 62.2 M 52.5 M 52.3 M 52.1 M 50.8 M 43.4 M 43.3 M 37.8 M 28.5 M 28.4 M 28.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-38.4 M 52.9 M - -3.53 M -41.6 M -38.4 M - -31 M -28.7 M -30.1 M - -15.8 M -23.5 M -11.7 M - -9.09 M -9.45 M -15.9 M - -7.28 M -6.55 M -9.18 M - -15 M -13.9 M -14.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

8.84 M 133 M - 54.3 M 8.84 M 3.12 M - 4.45 M 3.66 M 2.97 M - 3.68 M 4.79 M 4.49 M - 3.16 M 3.92 M 3.49 M - 3.18 M 3.38 M 3.08 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - 1.52 M - 1.56 M 1.49 M 1.47 M - 570 K 671 K 654 K - 740 K 731 K 694 K - 890 K 714 K 694 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-37.5 M 61.5 M - 1.77 M -37.5 M -35.4 M - -29.2 M -27.2 M -28.8 M - -14.9 M -22.8 M -9.23 M - -8.83 M -8.97 M -14.5 M - -7.08 M -6.35 M -9 M - -14.8 M -13.7 M -14.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - - - - 3 M 2.6 M 2.52 M - 1.76 M 1.43 M 1.12 M - 620 K 542 K 478 K - 205 K 203 K 150 K - 191 K 211 K 255 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-37.4 M 62 M - 2.07 M -37.3 M -35 M - -28.9 M -27 M -28.3 M - -14.6 M -22.5 M -8.66 M - -8.43 M -8.57 M -13.5 M - -2.34 M -3.16 M -7.39 M - -12.6 M -12.3 M -13.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

38.8 M 46.9 M - 40.1 M 38.8 M 30.1 M - 20.2 M 19.9 M 20.2 M - 10.6 M 9.24 M 7.79 M - 6.74 M 6.94 M 12.5 M - 4.88 M 4.42 M 5.34 M - 7.15 M 5.23 M 3.82 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Liquidia Corporation LQDA
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Liquidia Corporation plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Madrigal Pharmaceuticals Madrigal Pharmaceuticals
MDGL
$ 493.62 0.1 % $ 11.1 B usaUSA
MediWound Ltd. MediWound Ltd.
MDWD
$ 13.51 0.22 % $ 368 M israelIsrael
Mesoblast Limited Mesoblast Limited
MESO
$ 14.22 0.99 % $ 17.2 B australiaAustralia
MacroGenics MacroGenics
MGNX
$ 3.77 5.31 % $ 238 M usaUSA
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
$ 10.92 1.2 % $ 878 M usaUSA
Mirum Pharmaceuticals Mirum Pharmaceuticals
MIRM
$ 81.43 0.07 % $ 4.09 B usaUSA
Milestone Pharmaceuticals Milestone Pharmaceuticals
MIST
$ 0.78 0.25 % $ 82.9 M canadaCanada
MannKind Corporation MannKind Corporation
MNKD
$ 3.82 0.53 % $ 1.17 B usaUSA
MediciNova MediciNova
MNOV
$ 1.76 0.28 % $ 86.4 M usaUSA
Monopar Therapeutics Monopar Therapeutics
MNPR
$ 78.29 0.41 % $ 580 M usaUSA
Mereo BioPharma Group plc Mereo BioPharma Group plc
MREO
$ 0.39 2.16 % $ 311 M britainBritain
Merck & Co. Merck & Co.
MRK
$ 139.54 0.34 % $ 349 B usaUSA
Marker Therapeutics Marker Therapeutics
MRKR
$ 1.06 0.95 % $ 16.2 M usaUSA
Moderna Moderna
MRNA
$ 203.21 6.95 % $ 79 B usaUSA
Maravai LifeSciences Holdings Maravai LifeSciences Holdings
MRVI
$ 8.52 7.85 % $ 1.23 B usaUSA
Matinas BioPharma Holdings Matinas BioPharma Holdings
MTNB
$ 2.82 6.82 % $ 15.4 M usaUSA
RAPT Therapeutics RAPT Therapeutics
RAPT
- - $ 2.36 B usaUSA
Neurocrine Biosciences Neurocrine Biosciences
NBIX
$ 144.21 0.72 % $ 14.3 B usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
$ 25.1 0.16 % $ 1.2 T franceFrance
NuCana plc NuCana plc
NCNA
$ 1.06 2.75 % $ 11.9 B britainBritain
Minerva Neurosciences Minerva Neurosciences
NERV
$ 3.32 1.22 % $ 28.1 M usaUSA
Nektar Therapeutics Nektar Therapeutics
NKTR
$ 42.22 2.2 % $ 712 M usaUSA
Nkarta Nkarta
NKTX
$ 2.53 0.59 % $ 187 M usaUSA
NanoViricides NanoViricides
NNVC
$ 1.45 13.28 % $ 29.3 M usaUSA
Nurix Therapeutics Nurix Therapeutics
NRIX
$ 22.88 0.09 % $ 1.98 B usaUSA
Nuvation Bio Nuvation Bio
NUVB
$ 4.95 1.07 % $ 1.69 B usaUSA
Novavax Novavax
NVAX
$ 12.56 20.08 % $ 2.03 B usaUSA
Novo Nordisk A/S Novo Nordisk A/S
NVO
$ 37.54 0.59 % $ 167 B danmarkDanmark
Novartis AG Novartis AG
NVS
$ 140.93 0.01 % $ 273 B schweizSchweiz
NextCure NextCure
NXTC
$ 5.05 0.59 % $ 14.4 M usaUSA
Ocugen Ocugen
OCGN
$ 1.04 1.96 % $ 325 M usaUSA
Ocular Therapeutix Ocular Therapeutix
OCUL
$ 7.25 4.17 % $ 1.36 B usaUSA
Oragenics Oragenics
OGEN
$ 0.49 1.25 % $ 1.06 M usaUSA
Olema Pharmaceuticals Olema Pharmaceuticals
OLMA
$ 8.25 0.3 % $ 718 M usaUSA
Omeros Corporation Omeros Corporation
OMER
$ 18.9 1.56 % $ 1.2 B usaUSA
Oncolytics Biotech Oncolytics Biotech
ONCY
$ 0.6 1.21 % $ 57.5 M canadaCanada
ORIC Pharmaceuticals ORIC Pharmaceuticals
ORIC
$ 12.49 2.34 % $ 1.1 B usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
$ 4.55 1.34 % $ 188 M israelIsrael
Outlook Therapeutics Outlook Therapeutics
OTLK
$ 0.6 0.42 % $ 20.9 M usaUSA
Ovid Therapeutics Ovid Therapeutics
OVID
$ 2.34 0.21 % $ 305 M usaUSA
Passage Bio Passage Bio
PASG
$ 4.09 0.73 % $ 13.1 M usaUSA
Puma Biotechnology Puma Biotechnology
PBYI
$ 9.67 1.68 % $ 484 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
$ 1.49 0.62 % $ 1.95 M usaUSA
Vaxcyte Vaxcyte
PCVX
$ 73.82 30.7 % $ 10 B usaUSA
PDS Biotechnology Corporation PDS Biotechnology Corporation
PDSB
$ 1.2 60.32 % $ 55.7 M usaUSA
Pfizer Pfizer
PFE
$ 27.41 0.02 % $ 156 B usaUSA
Precigen Precigen
PGEN
$ 7.74 4.02 % $ 2.42 B usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 9.8 0.51 % $ 6.75 B niderlandNiderland
Phathom Pharmaceuticals Phathom Pharmaceuticals
PHAT
$ 6.7 1.77 % $ 489 M usaUSA
Phio Pharmaceuticals Corp. Phio Pharmaceuticals Corp.
PHIO
$ 0.99 0.6 % $ 5.92 M usaUSA